Figure 2: MTS assay dose-response curves for treatment of NCI/ADR-RES cells by daunorubicin (a P-gp substrate drug) (A), oxaliplatin (B) or cisplain (C) in the presence or absence of P-gp inhibitor cyclosporine A (5 µM).